Measurement of plasma beta-amyloid levels after glucose loading as diagnostic biomarker for Alzheimer disease

Measurement of plasma beta-amyloid levels after glucose loading as diagnostic biomarker for Alzheimer disease - Measurement of plasma beta-amyloid levels after glucose loading as diagnostic biomarker for Alzheimer disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004895

Enrollment

Registered

2011-01-18

Start date

2010-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: AD: Diagnosed as probable AD National Institute of Neurological and Communicative Disorders and Strokes-Alzheimers Disease and Related Disorders Association (NINCDS-ADRDA) MMSE: less than 23 MRI: no other abnormality than atrophy

Exclusion criteria

Exclusion criteria: Patients with diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Plasma beta amyloid levels after glucose loading	—

Countries

Japan

Contacts

Public ContactNaoyuki Sato

Osaka University Department of clinical gene therapyDepartment of geriatric medicine

nsato@cgt.med.osaka-u.ac.jp06-6879-3406

Outcome results